Literature DB >> 33420496

Publisher Correction: COVID-19 antibodies on trial.

Laura DeFrancesco1.   

Abstract

Entities:  

Year:  2021        PMID： 33420496      PMCID： PMC7793390          DOI： 10.1038/s41587-021-00813-x

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  4 in total

1.  A novel IgM intranasal intervention against SARS-CoV-2.

Authors:  Antony Yerabham; Mitchell Ho
Journal:  Antib Ther       Date:  2021-08-28

Review 2.  Molecular and Clinical Aspects of COVID-19 Vaccines and Other Therapeutic Interventions Apropos Emerging Variants of Concern.

Authors:  Khursheed Ul Islam; Thoraya Mohamed Elhassan A-Elgadir; Sarah Afaq; Tanveer Ahmad; Jawed Iqbal
Journal:  Front Pharmacol       Date:  2021-12-23       Impact factor: 5.810

Review 3.  Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.

Authors:  Jitendra Kumar Chaudhary; Rohitash Yadav; Pankaj Kumar Chaudhary; Anurag Maurya; Nimita Kant; Osamah Al Rugaie; Hoineiting Rebecca Haokip; Deepika Yadav; Rakesh Roshan; Ramasare Prasad; Apurva Chatrath; Dharmendra Singh; Neeraj Jain; Puneet Dhamija
Journal:  Cells       Date:  2021-10-29       Impact factor: 6.600

Review 4.  Severe Acute Respiratory Syndrome Type 2-Causing Coronavirus: Variants and Preventive Strategies.

Authors:  Mehmet Onur Aydogdu; Jennifer L Rohn; Nazila V Jafari; Francis Brako; Shervanthi Homer-Vanniasinkam; Mohan Edirisinghe
Journal:  Adv Sci (Weinh)       Date:  2022-01-17       Impact factor: 16.806
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.